|
WO2018140456A1
(en)
|
2017-01-24 |
2018-08-02 |
Northwestern University |
Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
|
|
EP3717077A1
(en)
|
2017-11-29 |
2020-10-07 |
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft |
Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
|
|
JP7340372B2
(ja)
|
2019-07-11 |
2023-09-07 |
浜松ホトニクス株式会社 |
光活性化アデニル酸シクラーゼ
|
|
US11518788B2
(en)
*
|
2020-07-10 |
2022-12-06 |
Avirus, Inc. |
Methods and compositions for treating and preventing viral infection
|
|
KR20220136369A
(ko)
*
|
2020-01-23 |
2022-10-07 |
에이바이러스 인코포레이티드 |
바이러스 감염의 치료 및 예방을 위한 방법 및 조성물
|
|
US20210236583A1
(en)
*
|
2020-02-03 |
2021-08-05 |
Yuntao Wu |
Targeting the renin-angiotensin system for treatment of environment-and pathogen-induced lung injury
|
|
EP4073243A4
(en)
*
|
2020-02-13 |
2024-08-07 |
Sichuan Baili Pharmaceutical Co. Ltd. |
RECOMBINANT ECA2-FC FUSION MOLECULES, METHODS OF PREPARATION AND USE THEREOF
|
|
TWI886211B
(zh)
*
|
2020-02-13 |
2025-06-11 |
美商西雅圖免疫公司 |
重組ace2-fc融合分子以及製造及使用彼等之方法
|
|
WO2021164723A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Lee Sheau Long |
Ginsenoside m1 as a modulator of angiotensin regulating enzymes and its use for treating diseases or conditions including symptoms caused by coronavirus
|
|
CN111474363A
(zh)
*
|
2020-02-22 |
2020-07-31 |
安徽华培生物科技有限公司 |
一种新型冠状病毒检测方法
|
|
US12123036B2
(en)
|
2020-02-26 |
2024-10-22 |
Northwestern University |
Soluble ACE2 variants and uses therefor
|
|
CA3173064A1
(en)
*
|
2020-02-27 |
2021-09-02 |
Huahui Health Ltd. |
Soluble ace2 and fusion protein, and applications thereof
|
|
WO2021170113A1
(zh)
*
|
2020-02-29 |
2021-09-02 |
南京金斯瑞生物科技有限公司 |
ACE-2-Fc融合蛋白治疗冠状病毒的方法
|
|
US11857620B2
(en)
|
2020-03-11 |
2024-01-02 |
Immunitybio, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
|
|
US20210284716A1
(en)
|
2020-03-11 |
2021-09-16 |
Immunitybio, Inc. |
ACE2-Fc Trap
|
|
US12285480B2
(en)
|
2020-03-11 |
2025-04-29 |
Nantcell, Inc. |
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
|
|
CN115244077B
(zh)
*
|
2020-03-11 |
2025-04-29 |
南特细胞公司 |
蛋白质治疗剂
|
|
CN116057176A
(zh)
*
|
2020-03-21 |
2023-05-02 |
赖瑞克斯生物科技公司 |
Ace2和补体途径的双特异性和三特异性功能分子及其用途
|
|
WO2021195009A1
(en)
*
|
2020-03-23 |
2021-09-30 |
Sapience Therapeutics, Inc. |
Peptide antagonists of ace2-binding proteins
|
|
CN113444710A
(zh)
*
|
2020-03-25 |
2021-09-28 |
上海英脉德医疗科技有限公司 |
ACE2-Fc融合蛋白及其用途
|
|
WO2021202456A1
(en)
*
|
2020-03-30 |
2021-10-07 |
The Wistar Institute Of Anatomy And Biology |
Synthetic soluble receptor mimics and methods of use for treatment of covid-19
|
|
WO2021197501A1
(zh)
*
|
2020-04-02 |
2021-10-07 |
创观（苏州）生物科技有限公司 |
病毒不易感动物
|
|
EP4126009A4
(en)
*
|
2020-04-03 |
2024-04-17 |
The University of North Carolina at Chapel Hill |
BINDING PROTEINS FOR USE AGAINST ACE2-TARGETED VIRUSES
|
|
US20230203466A1
(en)
*
|
2020-04-03 |
2023-06-29 |
Medgenome Inc. |
Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
|
|
US20230158125A1
(en)
*
|
2020-04-20 |
2023-05-25 |
Sorrento Therapeutics, Inc. |
Pulmonary Administration of ACE2 Polypeptides
|
|
WO2021237239A1
(en)
*
|
2020-05-18 |
2021-11-25 |
Northwestern University |
Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
|
|
US11773385B2
(en)
*
|
2020-05-19 |
2023-10-03 |
Children's Medical Center Corporation |
High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses
|
|
WO2021247675A1
(en)
*
|
2020-06-02 |
2021-12-09 |
Ngm Biopharmaceuticals, Inc. |
Coronavirus-binding agents and uses thereof
|
|
DE102020207224A1
(de)
|
2020-06-09 |
2021-12-09 |
Christoph Karle |
Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
|
|
CA3179834A1
(en)
*
|
2020-06-25 |
2021-12-30 |
David S. Block |
Ace2-fc fusion proteins and methods of use
|
|
WO2022008642A1
(en)
|
2020-07-08 |
2022-01-13 |
Apeiron Biologics Ag |
Treatment of sars-cov-2 infection with a combination of targets
|
|
WO2022012688A1
(en)
*
|
2020-07-17 |
2022-01-20 |
Shenzhen Bay Laboratory |
Ace2-ig fusion variants
|
|
KR102492081B1
(ko)
|
2020-07-28 |
2023-01-26 |
재단법인대구경북과학기술원 |
코로나바이러스 감염증 covid-19 치료용 펩타이드 및 이의 용도
|
|
KR20230065256A
(ko)
*
|
2020-08-06 |
2023-05-11 |
비온테크 에스이 |
코로나바이러스 s 단백질용 결합제
|
|
US20220041660A1
(en)
*
|
2020-08-06 |
2022-02-10 |
University Of Delaware |
Compositions and methods for sequestering viral particles in respiratory tract
|
|
US20230303654A1
(en)
*
|
2020-08-11 |
2023-09-28 |
City Of Hope |
Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
|
|
WO2022072757A1
(en)
*
|
2020-10-01 |
2022-04-07 |
Systimmune, Inc. |
Recombinant ace2-fc fusion molecules and methods of making and using thereof
|
|
WO2022075667A1
(ko)
*
|
2020-10-05 |
2022-04-14 |
한양대학교 산학협력단 |
안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
|
|
EP4228697A4
(en)
*
|
2020-10-16 |
2025-01-01 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
|
EP4249499A4
(en)
*
|
2020-11-20 |
2025-01-01 |
Daegu Gyeongbuk Institute Of Science and Technology |
Coronavirus infectious disease covid-19 therapeutic proteins ctp alpha, ctp beta, ctp gamma, ctp delta, and uses thereof
|
|
CA3200885A1
(en)
|
2020-11-23 |
2022-05-27 |
Genentech, Inc. |
Methods for modulating host cell surface interactions with sars-cov-2
|
|
WO2022119380A1
(ko)
*
|
2020-12-03 |
2022-06-09 |
주식회사 유틸렉스 |
신규한 ace2 변이체 및 그의 이용
|
|
EP4011387A1
(en)
*
|
2020-12-11 |
2022-06-15 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
|
|
US20220226489A1
(en)
|
2021-01-20 |
2022-07-21 |
Singh Biotechnology, Llc |
Therapeutics directed against coronavirus
|
|
CA3206022A1
(en)
*
|
2021-01-26 |
2022-08-04 |
Traian Sulea |
Ace2-receptor ectodomain fusion molecules and uses thereof
|
|
WO2022165245A1
(en)
*
|
2021-01-29 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and method of use of mutant ace2 decoy variants
|
|
CN115667506A
(zh)
*
|
2021-02-10 |
2023-01-31 |
西雅图免疫公司 |
重组ace2-fc融合分子及其制备和使用方法
|
|
WO2022207918A1
(en)
|
2021-04-02 |
2022-10-06 |
Apeiron Biologics Ag |
COVID-19 Therapy
|
|
US20240360181A1
(en)
*
|
2021-05-20 |
2024-10-31 |
Achelois Biopharma, Inc. |
Compositions and methods for multivalent surface display on enveloped particles
|
|
CN113324933B
(zh)
*
|
2021-06-01 |
2022-07-26 |
浙江大学 |
一种检测血管紧张素转换酶的方法及其应用
|
|
WO2022271863A1
(en)
*
|
2021-06-23 |
2022-12-29 |
Chan Zuckerberg Biohub, Inc. |
Coronavirus neutralizing compositions and associated methods
|
|
WO2023108040A2
(en)
*
|
2021-12-09 |
2023-06-15 |
Gliknik Inc. |
Ace2-fc fusion proteins and methods of use
|
|
WO2023201306A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating influenza infections
|
|
CA3256035A1
(en)
|
2022-04-14 |
2023-10-19 |
Invisishield Technologies Ltd. |
COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
CN116023509A
(zh)
*
|
2022-11-18 |
2023-04-28 |
中国药科大学 |
一种融合蛋白及其应用
|
|
DE202023100085U1
(de)
|
2023-01-09 |
2023-02-03 |
Sundararajan Gothandam |
Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie
|
|
CN118085110A
(zh)
*
|
2024-04-02 |
2024-05-28 |
中国药科大学 |
一种靶向肿瘤的融合蛋白及其应用
|